Insider buying last 90 days
No open-market insider purchases were filed for JAZZ in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every JAZZ insider filing, plotted on the chart in Gekko.Open JAZZ in Gekko
NASDAQ: JAZZ
Jazz Pharmaceuticals (JAZZ) Stock Analysis & Forecast
Sep 28 close
$238.28+0.33 (+0.1%)
Gekko Brief
AI summaryJazz Pharmaceuticals moves this week on record Q2 2026 results, with revenue reaching $1.2083 billion, up 16% year-over-year, driven by growth across its sleep, epilepsy and oncology products. Goldman Sachs initiates coverage with a buy rating and a $337 price target, citing strong performance and future growth prospects from new drug launches. Separately, the company extends and reprices its $1.895 billion term loan, moving the maturity to 2033 and reducing interest margins by 50 basis points, while also outlining a $3 billion to $5 billion opportunity for Ziihera alongside ongoing lifecycle work for Epidiolex.
The stock closes at $238.28, little changed on the day, sitting between its 50-day average of $248.62 and 200-day average of $210.58, reflecting a mixed short-term trend against a firmer longer-term one, with the 1-year return at 86.4%. The GekkoIndex reads 64.3, placing JAZZ in the Accumulation zone. Against a Gekko Fair Value of $304.40, the current price sits 21.7% below that level.
The next earnings report is scheduled for 4 November 2026, 36 days out and beyond a typical 20-trading-day hold; the prior report on 3 August showed an EPS of $4.89 against an estimate of $5.06, with an average absolute reaction of 8.1% across past reports. One trailblazer holder appears among current holdings. Seasonality data shows the next 20 trading days averaging a 4.6% gain over 5 years, rising in 4 of them. Consensus among 18 firms stands at 17 buy, 1 hold, 0 sell, with a consensus target of $292.81.
Written by AI and checked automatically against the figures on this page. Generated Sep 29, 2026 from the data above.
Jazz Pharmaceuticals price vs fair value
Close $238.28200-day averageGekko Fair Value $304.40
Jazz Pharmaceuticals quick facts
- Market cap
- $14.97B
- P/E ratio
- 16.1
- Forward P/E
- 10.9
- EPS, TTM
- $14.70
- Revenue, TTM
- $4.60B
- Profit margin
- 20.4%
- Dividend yield
- —
- Beta
- 0.36
- Volume
- 788,261 avg 768,641
- 1-year return
- +86.4%
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.7%
- 50-day average
- $248.62
- 200-day average
- $210.58
- Next earnings
- Nov 4 after close
- Shares outstanding
- 64.92M
Jazz Pharmaceuticals swing-trade checklist
Jazz Pharmaceuticals scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendmixed
Averages disagree
Close $238.28 sits between the 50-day ($248.62) and 200-day ($210.58) averages, or the averages disagree.
See the chart - GekkoIndexsupportive
64.3, Accumulation
Reading 64.3 is in the Accumulation zone.
See the GekkoIndex - Fair valuesupportive
21.7% below
Price is 21.7% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 36 days
Next report Nov 4, 2026, 36 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+4.6% on average
From this point in the calendar, the next 20 trading days averaged +4.6% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Jazz Pharmaceuticals stock chart and price history
Jazz Pharmaceuticals closed at $238.28 on Sep 28, 2026, +86.4% over the past year, inside a 52-week range of $125.79 to $266.38.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- −5.1%
- 3 months
- +0.2%
- 6 months
- +30.4%
- 1 year
- +86.4%
The full JAZZ chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open JAZZ in Gekko
Follow Jazz Pharmaceuticals through every session
Put JAZZ on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track JAZZ in GekkoFree for 7 days. No credit card required.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals researches, develops, and brings to market medicines sold across the United States, Europe, and other international regions. Its treatments address conditions such as narcolepsy and idiopathic hypersomnia, seizure disorders including Lennox-Gastaut and Dravet syndromes, several forms of leukemia and lymphoma, certain lung and biliary tract cancers, a specific type of glioma, and severe veno-occlusive disease, with products including Xywav, Epidiolex, Rylaze, Enrylaze, Zepzelca, Ziihera, Modeyso, Defitelio, and Vyxeos.
Beyond its marketed products, the company runs a pipeline of experimental treatments at various clinical stages, spanning cancers such as gastroesophageal adenocarcinoma, biliary tract cancer, breast cancer, acute myeloid leukemia, and rare tumor types, along with therapies aimed at glioma and absence epilepsy. It advances some of this work through licensing and collaboration arrangements with other firms, including Redx Pharma, Autifony Therapeutics, Zymeworks, Sumitomo Pharma, and Werewolf Therapeutics.
Jazz Pharmaceuticals was founded in 2003 and is based in Dublin, Ireland. Its shares are listed on the NASDAQ under the ticker JAZZ.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Website
- jazzpharma.com
Jazz Pharmaceuticals GekkoIndex: the smart money zone
Jazz Pharmaceuticals’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 64.3, in the Accumulation zone, up 2.8 points over five sessions.
64.3Accumulation
Up 2.8 points over five sessions.
Reading for Sep 28, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 25 | +0.9% | +2.4% | ||
| Accumulation (current zone) | 138 | +1.5% | +2.5% | ||
| Neutral | 464 | +0.6% | +2.8% | ||
| Distribution | 39 | −1.7% | −1.1% | ||
| Selling | 6 | Too few readings yet | |||
Average JAZZ share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Accumulation readings averaged +2.3% over 20 days. Past behaviour doesn’t guarantee future results.
Accumulation zone: Institutional interest building. About the five zones →
See every daily GekkoIndex reading plotted over the JAZZ price, zone by zone.Track JAZZ in Gekko
Is Jazz Pharmaceuticals stock overvalued? Gekko Fair Value
Jazz Pharmaceuticals trades 21.7% below Gekko Fair Value of $304.40, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Jazz Pharmaceuticals shares are worth, recalculated every trading day.
$304.40
Gekko Fair Value, Sep 26, 2026
21.7% Undervalued
Gekko Fair Value on every chart, with the gap to price updating daily.Open JAZZ in Gekko
Jazz Pharmaceuticals insider and Congress trading
No open-market insider purchases were filed for Jazz Pharmaceuticals, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in JAZZ were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for JAZZ, plotted on the chart in Gekko.Open JAZZ in Gekko
Buybacks
Jazz Pharmaceuticals has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2025
- $125.0M
- As a share of market cap
- 0.84%
From company filings.
Hedge funds and billionaires quarter ended Jun 30
1of the funds Gekko tracks holds JAZZ.
1added0opened0trimmed1sold out
Which funds are on each side, name by name.Unlock in Gekko
Jazz Pharmaceuticals earnings: next date and track record
Jazz Pharmaceuticals reports on Nov 4, 2026, after the close (36 days away), and beat the EPS estimate in 5 of its last 8 reports.
Next earnings report
Nov 4, 2026
Expected after the close, 36 days away
- EPS estimate
- $6.44
- Revenue estimate
- $1.21B
5 of 8reports beat the EPS estimate
±8.1%average move across the report
5 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 3, 2026 AI summary
- What they said
- Jazz Pharmaceuticals reported record Q2 2026 revenue of $1.2 billion, up 16% year-over-year, driven by double-digit growth across all key brands. Xywav net sales grew 13% to $471 million with ~17,125 active patients (+12% YoY). Epidiolex net sales grew 16% YoY to $292 million. The company is preparing for a potential zanidatamab launch with an August 25 PDUFA date for first-line HER2-positive metastatic GEA.
- Guidance
- Management raised full year 2026 revenue guidance based on strong first-half momentum. The company expressed confidence in sustained growth driven by its diversified portfolio, pending zanidatamab approval, and continued Xywav and Epidiolex demand.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 3, 2026 | $4.89 est $5.06 | $1.21B est $1.11B | +3.5% |
| May 5, 2026 | $6.34 est $4.66 | $1.20B est $1.17B | +9.9% |
| Feb 24, 2026 | $6.64 est $6.51 | — | +13.6% |
| Nov 5, 2025 | $8.13 est $5.95 | $1.13B est $1.11B | −2.7% |
| Aug 5, 2025 | −$8.25 est −$6.12 | $1.05B est $1.05B | −8.8% |
| May 6, 2025 | $1.68 est $4.66 | $897.8M est $1.06B | −14.2% |
| Feb 25, 2025 | $6.60 est $5.81 | $1.09B est $985.0M | +5.5% |
| Nov 6, 2024 | $6.61 est $5.50 | $1.05B est $1.06B | +6.9% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Jazz Pharmaceuticals stock forecast and analyst price targets
Analysts’ average 12-month price target for Jazz Pharmaceuticals is $292.81, +22.9% from the last close, from 18 firms rating the stock in the last 90 days.
$292.81consensus 12-month target, +22.9% from the last close
Now $238.28Avg $292.81
Low $229High $337
Each firm’s latest rating in the last 90 days: 18 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Sep 28 | Piper Sandler | $310 | +30.1% |
| Sep 25 | Bernstein | $229 | −3.9% |
| Sep 24 | Goldman Sachs | $337 | +41.4% |
| Sep 11 | UBS | $337 | +41.4% |
| Sep 10 | Barclays | $271 | +13.7% |
+2.5%average 20-day move after past Accumulation readings
+4.6%average move over the next 20 trading days in the last 5 years
±2.2%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Jazz Pharmaceuticals seasonality: the next 20 trading days
Over the next 20 trading days from Sep 26, Jazz Pharmaceuticals averaged +4.6% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +1.7% | 3 of 5 |
| Next 10 trading days | +2.2% | 3 of 5 |
| Next 15 trading days | +5.1% | 4 of 5 |
| Next 20 trading days | +4.6% | 4 of 5 |
| Next 30 trading days | +4.2% | 4 of 5 |
For scale, JAZZ’s typical 20-trading-day move in either direction is about 4.7%.
Jazz Pharmaceuticals market cap and key statistics
Jazz Pharmaceuticals’s market cap is $14.97B, with a P/E ratio of 16.1 and revenue of $4.60B over the last twelve months.
Valuation
- Market cap
- $14.97B
- P/E ratio
- 16.1
- Forward P/E
- 10.9
- EPS, TTM
- $14.70
- Gekko Fair Value
- $304.40
Trading
- Volume
- 788,261
- Avg volume, 20 days
- 768,641
- 52-week high
- $266.38
- 52-week low
- $125.79
- Shares outstanding
- 64.92M
Financials
- Revenue, TTM
- $4.60B
- Profit margin
- 20.4%
- Return on equity
- 22.1%
- Quarterly earnings growth, YoY
- +3.2%
Risk and income
- Beta
- 0.36
- Typical daily move
- ±2.2%
- Typical 20-day move
- ±4.7%
Jazz Pharmaceuticals stock news this week
Coverage of Jazz Pharmaceuticals this week reads positive: 7 positive, 0 neutral and 0 negative headlines.
- Jazz Pharmaceuticals stock reports record Q2 revenue growthAD HOC NEWS, Sep 24
- Goldman Sachs initiates Jazz Pharmaceuticals stock with buy rating By Investing.comInvesting.com UK, Sep 24
- Jazz Pharmaceuticals PLC (J7Z.HA) Analyst insights, Price targets and RecommendationsYahoo Finance UK, Sep 24
- Jazz Pharmaceuticals Extends And Reprices $1.895 Billion Term Loan B To 2033TradingView, Sep 23
- Five more years to repay its loans: Jazz Pharmaceuticals (JAZZ) also lowers borrowing margins.Stock Titan, Sep 23
- Jazz Pharmaceuticals (JAZZ) Gains Put Its Valuation Story Back In FocusSimply Wall Street, Sep 23
Jazz Pharmaceuticals peers
Jazz Pharmaceuticals’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| LLYEli Lilly | Neutral | 17.9% above |
| JNJJohnson & Johnson | Neutral | 0.5% above |
| ABBVAbbVie | Neutral | 23.3% above |
| MRKMerck | Neutral | 4.2% below |
| AZNAstraZeneca | Neutral | 39.9% below |
| PFEPfizer | Neutral | 4.0% below |
A peer links to its own page where one exists.
Jazz Pharmaceuticals stock FAQ
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $14.97B at the Sep 28, 2026 close of $238.28, with 64.92M shares outstanding. The shares trade on a P/E ratio of 16.1.
What is the Jazz Pharmaceuticals stock forecast?
The consensus analyst 12-month price target for Jazz Pharmaceuticals is $292.81, +22.9% from the last close. Of the 18 firms that rated the stock in the last 90 days, 17 rate it a buy, 1 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Jazz Pharmaceuticals stock overvalued or undervalued?
On Gekko’s estimate Jazz Pharmaceuticals is undervalued: the Sep 28, 2026 close of $238.28 is 21.7% below Gekko Fair Value of $304.40. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Jazz Pharmaceuticals report earnings next?
Jazz Pharmaceuticals is expected to report on Nov 4, 2026, after the market closes (36 days away). Analysts expect earnings of $6.44 per share on revenue of $1.21B. Jazz Pharmaceuticals beat the earnings estimate in 5 of its last 8 reports, moving 8.1% on average across the report.
What is Jazz Pharmaceuticals’s 52-week high and low?
Jazz Pharmaceuticals’s 52-week high is $266.38 and its 52-week low is $125.79; it closed at $238.28 on Sep 28, 2026, +86.4% over the past year.
Is Jazz Pharmaceuticals stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (gekkoindex, fair value, earnings risk and seasonality), 1 as mixed (trend). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Jazz Pharmaceuticals the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,380 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.